Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.

Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, Müllhaupt B, Wedemeyer H, Lacombe K, Matthews GV, Schultz M, Klein M, Hezode C, Estivill Mercade G, Kho D, Petoumenos K, Marks P, Tatsch F, Gabriela Pires Dos Santos A, Gane E; SMART-C Study Group.

J Hepatol. 2019 Oct 23. pii: S0168-8278(19)30612-9. doi: 10.1016/j.jhep.2019.10.010. [Epub ahead of print]

PMID:
31655134
2.

Short duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with recent HCV infection.

Martinello M, Orkin C, Cooke G, Bhagani S, Gane E, Kulasegaram R, Shaw D, Tu E, Petoumenos K, Marks P, Grebely J, Dore GJ, Nelson M, Matthews GV.

Hepatology. 2019 Oct 24. doi: 10.1002/hep.31003. [Epub ahead of print]

PMID:
31652357
3.

Emotion sharing in remote patient monitoring of patients with chronic kidney disease.

Huang R, Liu N, Nicdao MA, Mikaheal M, Baldacchino T, Albeos A, Petoumenos K, Sud K, Kim J.

J Am Med Inform Assoc. 2019 Oct 21. pii: ocz183. doi: 10.1093/jamia/ocz183. [Epub ahead of print]

PMID:
31633755
4.

Moving towards hepatitis C micro-elimination among people living with HIV in Australia: the CEASE study.

Martinello M, Yee J, Bartlett SR, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle J, Shaw D, Hellard M, Petoumenos K, Lin L, Marks P, Applegate T, Dore GJ, Matthews GV; CEASE study team.

Clin Infect Dis. 2019 Oct 4. pii: ciz985. doi: 10.1093/cid/ciz985. [Epub ahead of print]

PMID:
31585005
5.

Early initiation of antiretroviral therapy for people newly diagnosed with HIV infection in Australia: trends and predictors, 2004-2015.

McManus H, Callander D, Donovan B, Russell DB, O'Connor CC, Davies SC, Lewis DA, Hellard ME, Chen MY, Petoumenos K, Varma R, Cogle A, Boyd MA, Grulich A, Pollard J, Medland N, Fairley CK, Guy RJ.

Med J Aust. 2019 Apr;210(6):269-275. doi: 10.5694/mja2.50006. Epub 2019 Feb 18.

PMID:
30773651
6.

HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme.

Dharan NJ, Radovich T, Che S, Petoumenos K, Juneja P, Law M, Huang R, McManus H, Polizzotto MN, Guy R, Cronin P, Cooper DA, Gray RT.

BMC Public Health. 2019 Jan 3;19(1):13. doi: 10.1186/s12889-018-6325-5.

7.

Cardiovascular disease and diabetes in HIV-positive and HIV-negative gay and bisexual men over the age of 55 years in Australia: insights from the Australian Positive & Peers Longevity Evaluation Study.

Puhr R, Petoumenos K, Huang R, Templeton DJ, Woolley I, Bloch M, Russell D, Law MG, Cooper DA.

HIV Med. 2019 Feb;20(2):121-130. doi: 10.1111/hiv.12689. Epub 2018 Nov 26.

PMID:
30474916
8.

Association of anal symptoms with anal high grade squamous intraepithelial lesions (HSIL) among men who have sex with men: Baseline data from the study of the prevention of anal cancer (SPANC).

Goddard SL, Templeton DJ, Petoumenos K, Jin F, Hillman RJ, Law C, Roberts JM, Fairley CK, Garland SM, Grulich AE, Poynten IM; Study for the Prevention of Anal Cancer (SPANC) Research Team.

Cancer Epidemiol. 2019 Feb;58:12-16. doi: 10.1016/j.canep.2018.10.009. Epub 2018 Nov 12.

PMID:
30439602
9.

Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.

Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, Dalgard O, Lacombe K, Feld JJ, Bruneau J, Daulouede JP, Powis J, Bruggmann P, Matthews GV, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate TL, Crawford S, Dore GJ; D3FEAT Study Group.

Int J Drug Policy. 2018 Dec;62:94-103. doi: 10.1016/j.drugpo.2018.10.004. Epub 2018 Oct 29.

PMID:
30384028
10.

RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency.

Méndez C, Ledger S, Petoumenos K, Ahlenstiel C, Kelleher AD.

Retrovirology. 2018 Oct 4;15(1):67. doi: 10.1186/s12977-018-0451-0.

11.

Changes in plasma lipidome following initiation of antiretroviral therapy.

Trevillyan JM, Wong G, Puls R, Petoumenos K, Emery S, Mellett NA, Mundra PA, Meikle PJ, Hoy JF; ALTAIR Study Group.

PLoS One. 2018 Aug 29;13(8):e0202944. doi: 10.1371/journal.pone.0202944. eCollection 2018.

12.

Human immunodeficiency virus-infected young people in Australia: data from the Australian HIV Observational Database.

Hughes C, Puhr R, Ojaimi S, Petoumenos K, Bartlett AW, Templeton DJ, O'Connor CC, Gunathilake M, Woolley I.

Intern Med J. 2018 Dec;48(12):1447-1456. doi: 10.1111/imj.14040.

13.

Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.

Shepherd L, Ryom L, Law M, Petoumenos K, Hatleberg CI, d'Arminio Monforte A, Sabin C, Bower M, Bonnet F, Reiss P, de Wit S, Pradier C, Weber R, El-Sadr W, Lundgren J, Mocroft A; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.

Clin Infect Dis. 2019 Feb 1;68(4):650-657. doi: 10.1093/cid/ciy508.

PMID:
29912335
14.

Early Treatment of Primary HIV Infection Is Associated with Decreased Mortality.

Pinto AN, Grey P, Shaik A, Cooper DA, Kelleher AD, Petoumenos K.

AIDS Res Hum Retroviruses. 2018 Nov;34(11):936-941. doi: 10.1089/AID.2017.0284. Epub 2018 Jul 17.

15.

National characteristics and trends in antiretroviral treatment in Australia can be accurately estimated using a large clinical cohort.

Huang R, Petoumenos K, Gray RT, McManus H, Dharan N, Guy R, Cooper DA.

J Clin Epidemiol. 2018 Aug;100:82-91. doi: 10.1016/j.jclinepi.2018.04.015. Epub 2018 Apr 25.

16.

Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.

Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K, Applegate TL, Tu E, Marks P, Pagani N, Grebely J, Nelson M, Matthews GV.

J Viral Hepat. 2018 Oct;25(10):1180-1188. doi: 10.1111/jvh.12917. Epub 2018 May 8.

PMID:
29660224
17.

High rates of incident diabetes and prediabetes are evident in men with treated HIV followed for 11 years.

McMahon CN, Petoumenos K, Hesse K, Carr A, Cooper DA, Samaras K.

AIDS. 2018 Feb 20;32(4):451-459. doi: 10.1097/QAD.0000000000001709. Erratum in: AIDS. 2018 Sep 24;32(15):2267.

PMID:
29381559
18.

Multimorbidity, not human immunodeficiency virus (HIV) markers predicts unplanned admission among people with HIV in regional New South Wales.

Edmiston N, Petoumenos K, Smith DJ.

Intern Med J. 2018 Jun;48(6):706-713. doi: 10.1111/imj.13733.

PMID:
29316115
19.

Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years-The Australian Positive & Peers Longevity Evaluation Study (APPLES).

Petoumenos K, Huang R, Hoy J, Bloch M, Templeton DJ, Baker D, Giles M, Law MG, Cooper DA.

PLoS One. 2017 Sep 8;12(9):e0184583. doi: 10.1371/journal.pone.0184583. eCollection 2017.

20.

Funding antiretroviral treatment for HIV-positive temporary residents in Australia prevents transmission and is inexpensive.

Gray RT, Watson J, Cogle AJ, Smith DE, Hoy JF, Bastian LA, Finlayson R, Drummond FM, Whittaker B, Law MG, Petoumenos K.

Sex Health. 2018 Feb;15(1):13-19. doi: 10.1071/SH16237.

21.

Chronic kidney disease in Australian Human Immunodeficiency Virus-infected patients: Analysis of the Australian HIV Observational Database.

Cheung J, Puhr R, Petoumenos K, Cooper DA, Woolley I, Gunathilake M, Raymond N, Varma R, O'Connor CC, Gracey DM.

Nephrology (Carlton). 2018 Aug;23(8):778-786. doi: 10.1111/nep.13100.

22.

Evolution of HIV-1 surveillance drug resistance mutations over ten years in New South Wales, Australia.

Pinto A, Carrera A, Salem H, Thapa K, Shaik A, Petoumenos K, Cunningham P, Garsia R, Dwyer D, Cooper DA, Kelleher AD.

AIDS Res Hum Retroviruses. 2017 May 5. doi: 10.1089/AID.2016.0301. [Epub ahead of print]

PMID:
28474534
23.

CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy.

Petoumenos K, Choi JY, Hoy J, Kiertiburanakul S, Ng OT, Boyd M, Rajasuriar R, Law M; Australian HIV Observational Database; TREATAsia HIV Observational Database.

Antivir Ther. 2017;22(8):659-668. doi: 10.3851/IMP3155.

24.

The impact of changes in HIV management guidelines on time to treatment initiation in Australia.

Puhr R, Petoumenos K, Youds D, Law MG, Templeton DJ; Australian HIV Observational Database (AHOD) study group.

HIV Med. 2017 Oct;18(9):701-703. doi: 10.1111/hiv.12504. Epub 2017 Feb 22. No abstract available.

25.

HCV reinfection incidence among individuals treated for recent infection.

Martinello M, Grebely J, Petoumenos K, Gane E, Hellard M, Shaw D, Sasadeusz J, Applegate TL, Dore GJ, Matthews GV.

J Viral Hepat. 2017 May;24(5):359-370. doi: 10.1111/jvh.12666. Epub 2017 Jan 23.

26.

A longitudinal cohort study of HIV 'treatment as prevention' in gay, bisexual and other men who have sex with men: the Treatment with Antiretrovirals and their Impact on Positive And Negative men (TAIPAN) study protocol.

Callander D, Stoové M, Carr A, Hoy JF, Petoumenos K, Hellard M, Elliot J, Templeton DJ, Liaw S, Wilson DP, Grulich A, Cooper DA, Pedrana A, Donovan B, McMahon J, Prestage G, Holt M, Fairley CK, McKellar-Stewart N, Ruth S, Asselin J, Keen P, Cooper C, Allan B, Kaldor JM, Guy R.

BMC Infect Dis. 2016 Dec 12;16(1):752.

27.

Hospitalization for Anxiety and Mood Disorders in HIV-Infected and -Uninfected Gay and Bisexual Men.

Moore CL, Grulich AE, Prestage G, Gidding HF, Jin F, Petoumenos K, Zablotska IB, Poynten IM, Mao L, Law MG, Amin J.

J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):589-597.

28.

Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study.

Martinello M, Gane E, Hellard M, Sasadeusz J, Shaw D, Petoumenos K, Applegate T, Grebely J, Maire L, Marks P, Dore GJ, Matthews GV.

Hepatology. 2016 Dec;64(6):1911-1921. doi: 10.1002/hep.28844. Epub 2016 Oct 27.

PMID:
27639183
29.

Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.

Martinello M, Hellard M, Shaw D, Petoumenos K, Applegate T, Grebely J, Yeung B, Maire L, Iser D, Lloyd A, Thompson A, Sasadeusz J, Haber P, Dore GJ, Matthews GV.

Antivir Ther. 2016;21(5):465. doi: 10.3851/IMP3073. Epub 2016 Aug 10. No abstract available.

PMID:
27509356
30.

Smoking, alcohol and illicit drug use effects on survival in HIV-positive persons.

Petoumenos K, Law MG.

Curr Opin HIV AIDS. 2016 Sep;11(5):514-520. Review.

PMID:
27327615
31.

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.

Borges ÁH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES, Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P, Komati S, Kumar P, Lockman S, MacArthur RD, Maggiolo F, Matteelli A, Miro JM, Oka S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C, Lundgren JD.

Clin Infect Dis. 2016 Jul 15;63(2):268-80. doi: 10.1093/cid/ciw236. Epub 2016 Apr 18. Review.

32.

Risk factors associated with incident sexually transmitted infections in HIV-positive patients in the Australian HIV Observational Database: a prospective cohort study.

Mulhall BP, Wright ST, De La Mata N, Allen D, Brown K, Dickson B, Grotowski M, Jackson E, Petoumenos K, Foster R, Read T, Russell D, Smith DJ, Templeton DJ, Fairley CK, Law MG.

HIV Med. 2016 Sep;17(8):623-30. doi: 10.1111/hiv.12371. Epub 2016 Mar 28.

33.

Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.

Martinello M, Hellard M, Shaw D, Petoumenos K, Applegate T, Grebely J, Yeung B, Maire L, Iser D, Lloyd A, Thompson A, Sasadeusz J, Haber P, Dore GJ, Matthews GV.

Antivir Ther. 2016;21(5):425-34. doi: 10.3851/IMP3035. Epub 2016 Feb 11.

PMID:
26867206
34.

Patterns of Drug Use and Drug-related Hospital Admissions in HIV-Positive and -Negative Gay and Bisexual Men.

Moore CL, Gidding HF, Jin F, Mao L, Petoumenos K, Zablotska IB, Poynten IM, Prestage G, Law MG, Grulich AE, Amin J.

AIDS Behav. 2016 Oct;20(10):2372-2386. doi: 10.1007/s10461-016-1303-3.

35.

How do outcomes compare between women and men living with HIV in Australia? An observational study.

Giles ML, Zapata MC, Wright ST, Petoumenos K, Grotowski M, Broom J, Law MG, O'Connor CC.

Sex Health. 2016 Apr;13(2):155-61. doi: 10.1071/SH15124.

36.

Reducing Viral Load Measurements to Once a Year in Patients on Stable, Virologically Suppressive Cart Regimen: Findings from the Australian HIV Observational Database.

Rafiee M, Kariminia A, Wright S, Mills G, Woolley I, Smith D, Templeton DJ, Law MG, Petoumenos K.

J AIDS Clin Res. 2014 Dec;5(12). pii: 383.

37.

HIV-infection and comorbidities: a complex mix.

Petoumenos K, Law M.

Lancet HIV. 2015 Jul;2(7):e265-6. doi: 10.1016/S2352-3018(15)00082-X. Epub 2015 May 27. No abstract available.

PMID:
26423249
38.

Hospitalisation rates and associated factors in community-based cohorts of HIV-infected and -uninfected gay and bisexual men.

Moore CL, Grulich AE, Prestage G, Gidding HF, Jin F, Mao L, Petoumenos K, Zablotska IB, Poynten IM, Law MG, Amin J.

HIV Med. 2016 May;17(5):327-39. doi: 10.1111/hiv.12312. Epub 2015 Sep 6.

39.

Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD).

Templeton DJ, Wright ST, McManus H, Lawrence C, Russell DB, Law MG, Petoumenos K; Australian HIV Observational Database.

BMC Infect Dis. 2015 Aug 12;15:326. doi: 10.1186/s12879-015-1051-4.

40.

Estimating antiretroviral treatment coverage rates and viral suppression rates for homosexual men in Australia.

De La Mata NL, Mao L, De Wit J, Smith D, Holt M, Prestage G, Wilson DP, Petoumenos K.

Sex Health. 2015 Oct;12(5):453-7. doi: 10.1071/SH15037.

41.

Multimorbidity among people with HIV in regional New South Wales, Australia.

Edmiston N, Passmore E, Smith DJ, Petoumenos K.

Sex Health. 2015 Oct;12(5):425-32. doi: 10.1071/SH14070.

PMID:
26144504
42.

Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.

Alavi M, Spelman T, Matthews GV, Haber PS, Day C, van Beek I, Walsh N, Yeung B, Bruneau J, Petoumenos K, Dolan K, Kaldor JM, Dore GJ, Hellard M, Grebely J; ATAHC Study Group.

Int J Drug Policy. 2015 Oct;26(10):976-83. doi: 10.1016/j.drugpo.2015.05.003. Epub 2015 May 21.

43.

Temporal trends of time to antiretroviral treatment initiation, interruption and modification: examination of patients diagnosed with advanced HIV in Australia.

Wright ST, Law MG, Cooper DA, Keen P, McDonald A, Middleton M, Woolley I, Kelly M, Petoumenos K; Australian HIV Observational Database.

J Int AIDS Soc. 2015 Apr 10;18:19463. doi: 10.7448/IAS.18.1.19463. eCollection 2015.

44.

Subsidized optimal ART for HIV-positive temporary residents of Australia improves virological outcomes: results from the Australian HIV Observational Database Temporary Residents Access Study.

Petoumenos K, Watson J, Whittaker B, Hoy J, Smith D, Bastian L, Finlayson R, Sloane A, Wright ST, McManus H, Law MG.

J Int AIDS Soc. 2015 Feb 12;18:19392. doi: 10.7448/IAS.18.1.19392. eCollection 2015.

45.

Loss to follow-up in the Australian HIV Observational Database.

McManus H, Petoumenos K, Brown K, Baker D, Russell D, Read T, Smith D, Wray L, Giles M, Hoy J, Carr A, Law MG; Australian HIV Observational Database.

Antivir Ther. 2015;20(7):731-41. doi: 10.3851/IMP2916. Epub 2014 Nov 7.

46.

Is it time to rethink syphilis control?

Boyd MA, Donovan B, Prestage G, Chen M, Petoumenos K, Gray R, Guy R, Rogers GB, Bourne C, Klausner JD.

Clin Infect Dis. 2015 Jan 15;60(2):325-6. doi: 10.1093/cid/ciu813. Epub 2014 Oct 16. No abstract available.

PMID:
25323705
47.

High rates of sexually transmissible infections in HIV-positive patients in the Australian HIV Observational Database: a prospective cohort study.

Mulhall BP, Wright S, Allen D, Brown K, Dickson B, Grotowski M, Jackson E, Petoumenos K, Read P, Read T, Russell D, Smith DJ, Templeton DJ, Fairley CK, Law MG.

Sex Health. 2014 Sep;11(4):291-7. doi: 10.1071/SH13074.

48.

Dynamics of HCV RNA levels during acute hepatitis C virus infection.

Hajarizadeh B, Grebely J, Applegate T, Matthews GV, Amin J, Petoumenos K, Hellard M, Rawlinson W, Lloyd A, Kaldor J, Dore GJ; ATAHC study group.

J Med Virol. 2014 Oct;86(10):1722-9. doi: 10.1002/jmv.24010. Epub 2014 Jul 8.

49.

Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations.

Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin CA, El-Sadr W, d'Arminio Monforte A, Phillips AN, De Wit S, Kirk O, Dabis F, Pradier C, Lundgren JD, Law MG; D:A:D study group.

HIV Med. 2014 Nov;15(10):595-603. doi: 10.1111/hiv.12162. Epub 2014 May 19.

50.

Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.

Miller CJ, Baker JV, Bormann AM, Erlandson KM, Huppler Hullsiek K, Justice AC, Neuhaus J, Paredes R, Petoumenos K, Wentworth D, Winston A, Wolfson J, Neaton JD; INSIGHT SMART Study Group; ESPRIT Study Group.

PLoS One. 2014 Apr 11;9(4):e95061. doi: 10.1371/journal.pone.0095061. eCollection 2014.

Supplemental Content

Loading ...
Support Center